title: A spheroid-based 3-D culture model for pancreatic cancer drug testing, using the acid phosphatase assay.
abstract: Current therapy for pancreatic cancer is multimodal, involving surgery and chemotherapy. However, development of pancreatic cancer therapies requires a thorough evaluation of drug efficacy in vitro before animal testing and subsequent clinical trials. Compared to two-dimensional culture of cell monolayer, three-dimensional (3-D) models more closely mimic native tissues, since the tumor microenvironment established in 3-D models often plays a significant role in cancer progression and cellular responses to the drugs. Accumulating evidence has highlighted the benefits of 3-D in vitro models of various cancers. In the present study, we have developed a spheroid-based, 3-D culture of pancreatic cancer cell lines MIAPaCa-2 and PANC-1 for pancreatic drug testing, using the acid phosphatase assay. Drug efficacy testing showed that spheroids had much higher drug resistance than monolayers. This model, which is characteristically reproducible and easy and offers rapid handling, is the preferred choice for filling the gap between monolayer cell cultures and in vivo models in the process of drug development and testing for pancreatic cancer.
authors.affiliation: Tsinghua University, Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
authors.forename: Z
authors.initials: Z
authors.lastname: Wen
authors.forename: Q
authors.initials: Q
authors.lastname: Liao
authors.forename: Y
authors.initials: Y
authors.lastname: Hu
authors.forename: L
authors.initials: L
authors.lastname: You
authors.forename: L
authors.initials: L
authors.lastname: Zhou
authors.forename: Y
authors.initials: Y
authors.lastname: Zhao
mesh_terms: D000135:Acid Phosphatase / Q000378:metabolism*; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D018929:Cell Culture Techniques / Q000379:methods; D045744:Cell Line, Tumor / Q000187:drug effects / Q000201:enzymology; D002470:Cell Survival; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D004354:Drug Screening Assays, Antitumor / Q000379:methods*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D018874:Spheroids, Cellular / Q000187:drug effects* / Q000201:enzymology; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000135:Acid Phosphatase; D005472:Fluorouracil; D000093542:Gemcitabine
references.citation: J Biol Chem. 2008 May 9;283(19):13021-30
references.pmid: 18339627
references.citation: Cancer Sci. 2012 Mar;103(3):549-54
references.pmid: 22168771
references.citation: Chin Med J (Engl). 2010 Jul;123(14):1871-7
references.pmid: 20819570
references.citation: Cancer Res. 2009 Jul 15;69(14):5820-8
references.pmid: 19584296
references.citation: Cell Tissue Kinet. 1986 Sep;19(5):567-76
references.pmid: 3791377
references.citation: Cell Tissue Kinet. 1990 May;23(3):141-59
references.pmid: 2192799
references.citation: Int J Cancer. 1996 May 16;66(4):578-86
references.pmid: 8635877
references.citation: Int J Oncol. 2011 Aug;39(2):473-82
references.pmid: 21617862
references.citation: Clin Cancer Res. 2005 Apr 15;11(8):3094-101
references.pmid: 15837765
references.citation: Integr Biol (Camb). 2012 Apr;4(4):440-8
references.pmid: 22089949
references.citation: Nat Rev Mol Cell Biol. 2006 Mar;7(3):211-24
references.pmid: 16496023
references.citation: Biotechnol J. 2011 Dec;6(12):1488-96
references.pmid: 22102438
references.citation: J Transl Med. 2006 Mar 02;4:12
references.pmid: 16509995
references.citation: J Pharm Sci. 2011 Jan;100(1):59-74
references.pmid: 20533556
references.citation: Curr Opin Genet Dev. 2004 Feb;14(1):43-7
references.pmid: 15108804
references.citation: J Biomol Screen. 2004 Jun;9(4):273-85
references.pmid: 15191644
references.citation: Can J Physiol Pharmacol. 2004 Feb;82(2):146-52
references.pmid: 15052296
references.citation: Tissue Eng Part B Rev. 2010 Jun;16(3):351-9
references.pmid: 20092396
references.citation: Mol Imaging Biol. 2010 Aug;12(4):367-76
references.pmid: 19949979
references.citation: J Biomol Screen. 2007 Oct;12(7):925-37
references.pmid: 17942785
references.citation: Tissue Eng. 2006 Dec;12(12):3307-39
references.pmid: 17518671
references.citation: Curr Top Radiat Res Q. 1976 Jan;11(1):87-139
references.pmid: 128440
references.citation: Nat Protoc. 2009;4(3):309-24
references.pmid: 19214182
references.citation: Pancreas. 1997 Apr;14(3):237-48
references.pmid: 9094153
references.citation: J Cancer Res Clin Oncol. 2005 Nov;131(11):723-32
references.pmid: 16096850
references.citation: Ann Surg Oncol. 2007 Dec;14(12):3629-37
references.pmid: 17909916
references.citation: Int J Radiat Biol. 2007 Nov-Dec;83(11-12):849-71
references.pmid: 18058370
references.citation: Eur J Cancer. 2011 Sep;47 Suppl 3:S378-80
references.pmid: 21944022
references.citation: Crit Rev Oncol Hematol. 2000 Nov-Dec;36(2-3):193-207
references.pmid: 11033306
references.citation: Adv Exp Med Biol. 1994;361:619-25
references.pmid: 7597991
references.citation: Gynecol Oncol. 2009 Apr;113(1):143-8
references.pmid: 19135710
references.citation: Int J Radiat Oncol Biol Phys. 1992;22(4):689-92
references.pmid: 1544838
references.citation: Cancer Biol Ther. 2011 Aug 1;12(3):198-207
references.pmid: 21613822
references.citation: Cancer Res. 2003 Dec 1;63(23):8393-9
references.pmid: 14679001
references.citation: Cancer Sci. 2010 Dec;101(12):2637-43
references.pmid: 20849469
references.citation: J Natl Cancer Inst. 1971 Jan;46(1):113-20
references.pmid: 5101993
references.citation: Chin Med J (Engl). 2011 Jan;124(2):262-7
references.pmid: 21362378
references.citation: J Biotechnol. 2010 Jul 1;148(1):3-15
references.pmid: 20097238
references.citation: Phys Rev Lett. 2011 Oct 28;107(18):188102
references.pmid: 22107677